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versus placebo prolonged overall survival with favorable safety in castration-resistant
prostate cancer patients with symptomatic bone metastases. Long-term radium-223
monitoring underlies a comprehensive safety and risk/benefit assessment.
Objective: To report updated ALSYMPCA safety, including long-term safety up to 3 yr
after the ﬁrst injection.
Design, setting, and participants: Safety analyses from phase 3 randomized ALSYMPCA
trial included patients receiving 1 study-drug injection (600 radium-223 and 301 pla-
cebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up
starting 12 wk after the last study-drug injection, to 3 yr from the ﬁrst injection. Forty-
eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up,
with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr.
Outcomemeasurements and statistical analysis: All adverse events (AEs)were collected
until 12 wk after the last injection; subsequently, only treatment-related AEs were
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Surrey SM2 5PT, UK. Tel. +44 (208) 6613425; Fax: +44 (208) 6438809.
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0302-2838/# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
collected. Additional long-term safety was assessed by development of acute myelogenous
leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, and secondary malig-
nancies. Data analysis used descriptive statistics.
Results and limitations: During treatment to 12 wk following the last injection, 564/600
(94%) radium-223 and 292/301 (97%) placebo patients had treatment-emergent AEs
(TEAEs). Myelosuppression incidence was low. Grade 3/4 hematologic TEAEs in
radium-223 and placebo groups were anemia (13% vs 13%), neutropenia (2% vs 1%), and
thrombocytopenia (7% vs 2%). Ninety-eight of 600 (16%) radium-223 and 68/301 (23%)
placebo patients experienced grade 5 TEAEs. Long-term follow-up showed no AML, MDS, or
new primary bone cancer; secondary non–treatment-relatedmalignancies occurred in four
radium-223 and three placebo patients. One radium-223 patient had aplastic anemia 16mo
after the last injection. No other cases were observed. Limitations include short (3-yr)
follow-up.
Conclusions: Final long-term safety ALSYMPCA analysis shows that radium-223 remained
well tolerated, with low myelosuppression incidence and no new safety concerns.
Patient summary: Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial
ﬁndings show that radium-223 remained well tolerated during treatment and up to 3 yr
after each patient’s ﬁrst injection.
# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Radium-223 is a first-in-class targeted alpha therapy for
castration-resistant prostate cancer (CRPC) and symptom-
atic bone metastases with minimal myelosuppressive
effects [1,2]. The relatively large size of alpha particles,
coupled with the high linear energy transfer of emitted
particles, results in a short path length and localized area of
cell destruction (<100 mm; 2–10 cell diameters), inducing
predominantly nonrepairable double-stranded DNA breaks
[3]. Unlike beta particles emitted from strontium-89 and
samarium-153, the much shorter range of alpha particles
spares hematopoietic bone marrow and produces a more
tolerable safety profile.
Agents approved for use in patients with CRPC have been
associated with significant toxicities. These include the
taxanes docetaxel and cabazitaxel, which have a range of
chemotherapy-related effects [4–6]. Beta-emitting radio-
pharmaceuticals such as strontium-89 and samarium-153,
used for pain palliation in CRPC patients with bone
metastases, are associated with significant myelosuppres-
sion [1,2,7,8].
In the phase 3 Alpharadin in Symptomatic Prostate
Cancer (ALSYMPCA) trial, radium-223 plus best standard of
care (BSoC), versus placebo plus BSoC, prolonged median
overall survival by 3.6 mo (14.9 vs 11.3 mo; p < 0.001)
[9]. Additionally, radium-223 was well tolerated and
associated with a low incidence of grade 3 or 4 myelosup-
pression (radium-223 vs placebo: anemia, 13% vs 13%;
neutropenia, 2% vs 1%; and thrombocytopenia, 7% vs 2%).
Based on ALSYMPCA efficacy and safety results, radium-223
was approved for treatment of patients with CRPC and
symptomatic bone metastases and no known visceral
metastases.
Although these radium-223 safety data are reassuring,
long-term safety monitoring of radium-223 is essential to
provide a comprehensive safety profile, including post-
treatment adverse event (AE) data, and to afford clinicians a
higher level of confidence in radium-223 overall safety. This
article reports radium-223 final safety data fromALSYMPCAtrial. Data presented are updated from previously reported
safety results [9], with additional long-term safety from
12wk after each patient’s last injection up to 3 yr after their
first injection.
2. Patients and methods
2.1. Patients and study design
Complete ALSYMPCA studymethods were previously reported [9,10] and
are summarized here (ClinicalTrials.gov number, NCT00699751).
Eligible patients had symptomatic and progressing CRPC and 2 bone
metastases with no visceral metastases, Eastern Cooperative Oncology
Group performance status 2, life expectancy 6 mo, and adequate
baseline hematologic, renal, and liver functions. Patients either had
previous docetaxel treatment or were unsuitable for or declined
docetaxel. Patients were randomized 2:1 to radium-223 50 kBq/kg
(55 kBq/kg following the National Institute of Standards and Technology
[NIST] update) [11] plus BSoC or placebo plus BSoC every 4 wk for 24 wk
(six injections; Fig. 1). BSoC was deﬁned as routine care provided at each
center and included external beam radiation therapy for bone pain as
indicated. Randomization was done with an interactive voice response
system, taking into account trial stratiﬁcation factors. After study
unblinding, placebo patients who still met the eligibility criteria were
offered radium-223 (placebo crossover patients).
The long-term safety follow-up period started 12 wk after the last
study-drug injection (end of treatment) and continued until 3 yr from
the ﬁrst study-drug injection. During follow-up, patients were evaluated
every 2 mo for 6 mo, then every 4 mo for up to 3 yr (Fig. 1).
The primary ALSYMPCA end point was overall survival; secondary
end points included acute and long-term safety.
2.2. Study assessments
Safety assessments included AEs, graded according to Common
Terminology Criteria for Adverse Events version 3.0. Treatment-
emergent AEs (TEAEs) included all AEs that started after the ﬁrst
injection up to 12 wk after the last injection. Post-treatment follow-up
AEs were those that started >12 wk after the last injection during long-
term safety follow-up and were reported only if considered treatment
related by the investigator. Additional long-term safety data were
assessed by occurrence of speciﬁc diseases, including acute myeloge-
nous leukemia (AML), myelodysplastic syndrome (MDS), aplastic
[(Fig._1)TD$FIG]
W0 W8W4 W16W12 W20
6 injections; 1 every 4 wk
Treatment period Designated long-term follow-up
W24 Y3
9 follow-up visits (every 2nd month
for first 0.5 yr, every 4 mo up to 3 yr)
Fig. 1 – ALSYMPCA study timeline. ALSYMPCA = Alpharadin in Symptomatic Prostate Cancer; W = week; Y = year.
E U RO P E AN URO L OGY 7 3 ( 2 0 1 8 ) 4 2 7 – 4 3 5 429anemia, new primary bone cancer, and any secondary malignancies.
Deaths were considered to be related (probably or possibly) or unrelated
to study treatment, as judged by the investigator.
2.3. Statistical analyses
Statistical methods used in ALSYMPCA study have been described (July
2011 database lock) [9]. Data presented here include updated safety data
collected for the entire study period (treatment and follow-up to 3 yr
from the ﬁrst study-drug injection) up to the October 2014 database
[(Fig._2)TD$FIG]
Safety population
Radium-223, n = 600a; placebo, n = 301  
Patients who entered 3-yr follow-up
Radium-223, n = 405 (68%); placebo, n = 167 (55%)
Patients who completed 3-yr follow-up
Radium-223, n = 48 (12%); placebo, n = 12 (7%)
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Fig. 2 – CONSORT diagram. a One patient in the placebo group received one inj
analysis. b Two (<1%) radium-223 and two (<1%) placebo patients’ study compllock, including the 24 placebo crossover patients who were offered
radium-223 after study unblinding.
Safety analyses during the treatment period (up to 12 wk following
the last study-drug injection) and long-term safety follow-up period
(starting 12 wk after the last injection and continuing until 3 yr from the
ﬁrst study-drug injection) are presented by treatment group and
summarized separately.
All patients who received radium-223 were combined (main study
and placebo crossover [patients originally randomized to placebo and
offered radium-223 after study unblinding]). Patient data are presentedPatients who did not enter 3-yr follow-up
dium-223, n = 195 (33%); placebo, n = 134 (45%)
atients who discontinued during follow-upb
ium-223, n = 355 (88%); placebo, n = 153 (92%)
PlaceboRadium-223 r discontinuation, n (%) 
105 (63)285 (70) 
equest 7 (4)29 (7) 
 progression 8 (5)14 (3) 
ollow-up 0 (0)9 (2) 
ator request 4 (2)6 (1) 
 event 2 (1)3 (1) 
27 (16)8 (2) 
0 (0)1 (<1) 
ection of radium-223 (week 0) and is included in the radium-223 safety
etion pages were not received.
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treatment and to evaluate whether the few placebo crossover patients
affect the overall safety ﬁndings. Separate safety analyses were
performed on the patient subset that entered the long-term safety
follow-up period. Demographics, disposition, and safety variables
were summarized descriptively. Data were analyzed using SAS
Version 9.1.3.3. Results
3.1. Patients
The safety population included 901 patients (600
radium-223 and 301 placebo) who received one or more
study-drug injections (Fig. 2). Baseline demographics and
clinical characteristics were well balanced across treatment
groups (Table 1).
Median follow-up time from the first injection up to 3 yr
was 13 mo (range, 0–36 mo) for radium-223 patients and
9 mo (range, 0–36 mo) for placebo patients.Table 1 – Baseline demographics and clinical characteristics a (safety p
Radium-223
N = 600
Age
Median (IQR), yr 71 (64–76)
>75 yr, n (%) 169 (28)
Total ALP level, n (%)
<220 U/l 345 (58)
220 U/l 255 (43)
Current use of bisphosphonates at study entry, yes, n (%) 244 (41)
Prior docetaxel use, yes, n (%) 347 (58)
ECOG performance status, n (%) b
0 162 (27)
1 366 (61)
2 72 (12)
WHO ladder for cancer pain, n (%)
0–1—no pain or mild pain; no opioid use 263 (44)
2—moderate pain, occasional opioid use 148 (25)
3—severe pain, regular daily opioid use 189 (32)
Extent of disease, n (%)
<6 metastases 100 (17)
6–20 metastases 252 (42)
>20 metastases/superscan c,d 246 (41)
EBRT within 12 wk of screening, n (%)
Yes 98 (16)
No 502 (84)
Median biochemical values (IQR) e
Albumin, g/l 40 (37–43)
Total ALP, U/l 206 (104–418
LDH, U/l 313 (223–464
PSA, mg/l 146 (49–419)
Median hematologic values (IQR) e
Hemoglobin, g/dl 12 (11–13)
Neutrophils (absolute), 109/l 5 (3–6)
Platelets, 109/l 244 (198–302
ALP = alkaline phosphatase; EBRT = external beam radiation therapy; ECOG = Ea
dehydrogenase; PSA = prostate-speciﬁc antigen; WHO =World Health Organizati
a Percentages may not sum to 100% due to rounding.
b Value recorded at screening.
c Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the
d Based on the intent-to-treat population (radium-223, N = 614; placebo, N = 307
e Value recorded at week 0. If this value was missing, then the value recorded at
total ALP, 35–105 U/l; LDH, 115–225 U/l; PSA, 0–3.999 mg/l; hemoglobin, 13.4–173.2. Updated safety during treatment period
Overall in this updated analysis of the original ALSYMPCA
study publication [9], 564/600 (94%) radium-223 and
292/301 (97%) placebo patients had one or more TEAEs
during the treatment period up to 12 wk following the
last injection (Table 2). Radium-223 was associated with a
low incidence of myelosuppression; grade 3/4 hemato-
logic TEAEs in radium-223 and placebo groups were
anemia in 13% and 13%, neutropenia in 2% and 1%, and
thrombocytopenia in 7% and 2%, respectively. Grade
5 TEAEs occurred in 98/600 (16%) radium-223 and
68/301 (23%) placebo patients (Table 2); disease progres-
sion (malignant neoplasm progression) was the most
frequently reported TEAE leading to death in both
radium-223 and placebo groups (54/600 [9%] and
35/301 [12%], respectively).
Secondary malignancies, defined as new cancers histo-
logically different from the primary cancer, or complica-
tions from previously existing cancer were identified inopulation)
Placebo
N = 301
Radium-223
(main study and placebo crossover)
N = 624
71 (65–77) 71 (64–76)
88 (29) 176 (28)
165 (55) 345 (55)
136 (45) 255 (41)
120 (40) 244 (39)
171 (57) 347 (56)
77 (26) 165 (26)
183 (61) 381 (61)
40 (13) 78 (13)
138 (46) 274 (44)
78 (26) 155 (25)
85 (28) 195 (31)
37 (12) 101 (16)
144 (48) 259 (42)
119 (40) 262 (42)
47 (16) 98 (16)
254 (84) 502 (80)
40 (37–43) 40 (37–43)
) 224 (124–459) 198 (103–418)
) 336 (232–484) 311 (221–462)
173 (59–472) 147 (49–433)
12 (11–13) 12 (11–13)
5 (3–6) 5 (3–6)
) 240 (189–313) 244 (197–302)
stern Cooperative Oncology Group; IQR = interquartile range; LDH = lactate
on.
tracer without renal and background activity.
).
screening was used. The normal values were as follows: albumin, 36–45 g/l;
.0 g/dl; neutrophils (absolute), 2–7.5  109/l; platelets, 150–350  109/l.
Table 2 – Adverse events occurring during treatment period, up to 12 wk after last injection (safety population) a
TEAEs n (%) Radium-223
N = 600
Placebo
N = 301
Radium-223 (main study and
placebo crossover)
N = 624
All Gr Gr 3/4 Gr 5 All Gr Gr 3/4 Gr 5 All Gr Gr 3/4 Gr 5
1 TEAE 564 (94) 350 (58) 98 (16) 292 (97) 194 (65) 68 (23) 587 (94) 366 (59) 103 (17)
Hematologic b
Anemia 187 (31) 79 (13) 0 93 (31) 39 (13) 1 (<1) 196 (31) 81 (13) 0
Neutropenia 30 (5) 13 (2) 0 3 (1) 2 (1) 0 32 (5) 15 (2) 0
Thrombocytopenia 69 (12) 39 (7) 0 17 (6) 6 (2) 0 72 (12) 42 (7) 0
Nonhematologic b
Bone pain 310 (52) 132 (22) 0 192 (64) 79 (26) 0 321 (51) 136 (22) 0
Diarrhea 154 (26) 8 (1) 0 45 (15) 6 (2) 0 161 (26) 8 (1) 0
Nausea 215 (36) 10 (2) 0 102 (34) 6 (2) 0 226 (36) 10 (2) 0
Vomiting 116 (19) 10 (2) 0 41 (14) 7 (2) 0 119 (19) 10 (2) 0
Constipation 109 (18) 7 (1) 0 64 (21) 4 (1) 0 111 (18) 7 (1) 0
Fatigue 160 (27) 27 (5) 0 79 (26) 18 (6) 0 169 (27) 27 (4) 0
Peripheral edema 78 (13) 10 (2) 0 30 (10) 4 (1) 0 80 (13) 10 (2) 0
Weight decreased 73 (12) 5 (1) 0 44 (15) 5 (2) 0 75 (12) 5 (1) 0
Anorexia 109 (18) 9 (2) 0 54 (18) 2 (1) 0 113 (18) 10 (2) 0
Malignant neoplasm progression 78 (13) 14 (2) 54 (9) 46 (15) 5 (2) 35 (12) 81 (13) 15 (2) 56 (9)
Urinary tract infection 49 (8) 9 (2) 0 28 (9) 7 (2) 1 (<1) 54 (9) 9 (1) 0
Dizziness 45 (8) 2 (<1) 0 26 (9) 2 (1) 0 47 (8) 2 (<1) 0
Pyrexia 40 (7) 3 (1) 0 19 (6) 3 (1) 0 40 (6) 3 (1) 0
Spinal cord compression 25 (4) 20 (3) 1 (<1) 23 (8) 17 (6) 0 26 (4) 21 (3) 1 (<1)
Decreased appetite 36 (6) 2 (<1) 0 13 (4) 0 0 37 (6) 2 (<1) 0
Asthenia 36 (6) 6 (1) 0 18 (6) 4 (1) 0 38 (6) 6 (1) 0
Urinary retention 27 (5) 10 (2) 0 19 (6) 6 (2) 0 30 (5) 11 (2) 0
General physical health deterioration 30 (5) 11 (2) 6 (1) 21 (7) 11 (4) 2 (1) 31 (5) 11 (2) 7 (1)
Hematuria 29 (5) 7 (1) 0 16 (5) 3 (1) 0 29 (5) 7 (1) 0
Arthralgia 29 (5) 3 (1) 0 11 (4) 1 (<1) 0 29 (5) 3 (1) 0
Cough 28 (5) 0 0 11 (4) 0 0 29 (5) 0 0
Insomnia 31 (5) 0 0 17 (6) 1 (<1) 0 31 (5) 0 0
Dyspnea 49 (8) 11 (2) 1 (<1) 26 (9) 7 (2) 3 (1) 49 (8) 11 (2) 1 (<1)
Muscular weakness 9 (2) 3 (1) 0 16 (5) 6 (2) 0 11 (2) 3 (1) 0
Pathologic fracture 24 (4) 13 (2) 0 16 (5) 10 (3) 0 26 (4) 14 (2) 0
Pneumonia 21 (4) 11 (2) 4 (1) 16 (5) 7 (2) 0 22 (4) 11 (2) 4 (1)
ALSYMPCA = Alpharadin in Symptomatic Prostate Cancer; Gr = grade; TEAE = treatment-emergent adverse event.
a Updated from previously reported ALSYMPCA safety data.
b Occurring in 5% of patients in either study group.
E U RO P E AN URO L OGY 7 3 ( 2 0 1 8 ) 4 2 7 – 4 3 5 431both treatment groups. In the radium-223 group, one patient
had carcinoma of unknown origin, one had squamous cell
carcinoma, one had intestinal adenocarcinoma, and two
had skin neoplasms (types unknown). In the placebo group,
one patient had neoplasm of unknown origin and one had
gastric cancer.
3.3. Patients who entered long-term safety follow-up
Of 901 patients in the ALSYMPCA safety population, 572
(405 radium-223 and 167 placebo) entered the designated
3-yr long-term safety follow-up period. Baseline demo-
graphic and clinical characteristics of those patients were
generally similar across treatment groups (Table 3). During
long-term safety follow-up, 185/405 (46%) radium-223 and
80/167 (48%) placebo patients had subsequent anticancer
therapy following study treatment (Supplementary
Table 1). The most common anticancer therapies received
were abiraterone (radium-223, 92/405 [23%]; placebo,
31/167 [19%]) and docetaxel (radium-223, 92/405 [23%];
placebo, 36/167 [22%]). Radiotherapy was received by
178/405 (44%) radium-223 and 84/167 (50%) placebo
patients (Supplementary Table 1).Most patients entering follow-up had completed all six
injections of study treatment (radium-223, 337/405 [83%];
placebo, 118/167 [71%]; Supplementary Table 2). The
primary reason for not receiving all six injections was
AEs (radium-223, 27/405 [7%]; placebo, 17/167 [10%]).
Additional reasons for not receiving all six injections
included investigator request (radium-223, 12/405 [3%];
placebo, 16/167 [10%]), patient request (radium-223,
15/405 [4%]; placebo, 9/167 [5%]), and other (radium-223,
14/405 [3%]; placebo, 7/167 [4%]).
All patients were followed for up to 3 yr after their first
injection. The percentages of patients alive at the start of 1,
2, and 3 yr following the first treatment injection were
higher for radium-223 than for placebo patients (326/405
[80%] and 118/167 [71%], 136/405 [34%] and 40/167 [24%],
and 55/405 [14%] and 12/167 [7%], respectively; Supple-
mentary Table 3).
During the 3-yr safety follow-up period, 355/405 (88%)
radium-223 and 153/167 (92%) placebo patients discon-
tinued from the study. The primary reason for discontinua-
tion was death (radium-223, 285/405 [70%]; placebo,
105/167 [63%]); other reasons are shown in Supplementary
Table 4.
Table 3 – Demographics and baseline characteristics of patients who entered 3-yr long-term safety follow-up period a (safety population)
Radium-223
n = 405
Placebo
n = 167
Radium-223
(main study and placebo crossover)
n = 420
Age, median (IQR), yr 71 (64–76) 70 (65–76) 71 (64–76)
Total ALP, n (%)
<220 U/l 253 (62) 114 (68) 253 (60)
220 U/l 152 (38) 53 (32) 152 (36)
Current bisphosphonates, yes, n (%) 168 (41) 73 (44) 168 (40)
Prior docetaxel, yes, n (%) 234 (58) 94 (56) 234 (56)
ECOG performance status, n (%) b
0 118 (29) 54 (32) 120 (29)
1 249 (61) 100 (60) 259 (62)
2 38 (9) 13 (8) 41 (10)
WHO ladder for cancer pain, n (%)
0–1—no pain or mild pain, no opioid use 190 (47) 83 (50) 199 (47)
2—moderate pain, occasional opioid use 106 (26) 47 (28) 109 (26)
3—severe pain, regular daily opioid use 109 (27) 37 (22) 112 (27)
EBRT within 12 wk of screening, yes, n (%) 55 (14) 20 (12) 55 (13)
Extent of disease, n (%)
<6 metastases 87 (21) 29 (17) 88 (21)
6–20 metastases 173 (43) 88 (53) 177 (42)
>20 metastases/superscan 143 (35) 50 (30) 153 (36)
Median biochemical values (IQR)
Albumin, g/l 40 (37–43) 41 (38–43) 40 (38–43)
Total ALP, U/l 159 (93–333) 164 (95–322) 157 (92–331)
LDH, U/l 272 (205–386) 300 (203–421) 270 (205–386)
PSA, mg/l 104 (40–334) 116 (36–426) 104 (40–337)
Median hematologic values (IQR)
Hemoglobin, g/dl 13 (11–13) 13 (12–13) 13 (11–13)
Neutrophils (absolute), 109/l 4 (3–6) 4 (3–6) 4 (3–6)
Platelets, 109/l 244 (198–299) 240 (194–306) 244 (198–298)
ALP = alkaline phosphatase; EBRT = external beam radiation therapy; ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; LDH = lactate
dehydrogenase; PSA = prostate-speciﬁc antigen; WHO =World Health Organization.
a Percentages may not sum to 100% due to rounding.
b Value recorded at screening.
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Post-treatment treatment-related AEs in patients who
entered 3-yr long-term safety follow-up are presented in
Table 4. Overall incidence of myelosuppression was 3%;
nonhematologic AEs were 1%.
There were no reports of AML or MDS. Aplastic
anemia based on bone marrow biopsy was reported in
one radium-223 patient at follow-up visits 5 and 6 (16 and
20 mo from the last injection) and was considered by the
investigator to be probably related to study drug. No new
primary bone cancer was reported. In addition to the
secondary malignancies reported during treatment, a
number of secondary malignancies were reported during
long-term follow-up and considered not related to study
drug. In the radium-223 group, one patient had bladder
cancer reported at follow-up visit 1 (3 mo after the last
injection) and one had lymph node metastases of unknown
origin reported at follow-up visit 6 (20 mo after the last
injection). In the placebo group, one patient had squamous
cell carcinoma of the left hand reported at follow-up visit 2
(6 mo after the last injection), one had adenocarcinoma of
the rectum and adenocarcinoma of the sigmoid colon
reported at follow-up visit 4 (12 mo after the last injection),
and one had skin cancer (type unknown) reported at follow-
up visits 7 and 8 (24 and 28 mo after the last injection). Inthe placebo crossover group, one patient had squamous cell
carcinoma of the skin reported at follow-up visit 1 (3 mo
after the last injection) and one had meningioma reported
at follow-up visit 2 (6 mo after the last injection).
Cumulative incidence rates for hematologic and non-
hematologic AEs of interest and for secondary malignancies
were low (Supplementary Table 5 and Supplementary
Fig. 1A–C).
3.5. Deaths during study (treatment and safety follow-up
periods)
During the treatment period, 111/600 (19%) radium-223
and 78/301 (26%) placebo patients died (Supplementary
Table 6). Deaths of two radium-223 patients were consid-
ered possibly related to study treatment: one patient who
received two injections died of possible myocardial infarc-
tion or bowel ischemia 8 wk after the first injection; one
patient who received one injection died of general
deterioration of health with multiple organ failure within
4 wk after the first injection.
During long-term safety follow-up, a higher percentage
of placebo patients than radium-223 patients died or
dropped out (Supplementary Table 3). Deaths of two
radium-223 patients were considered by the investigator
to be related to study treatment. Both patients received all
Table 4 – Post-treatment treatment-related AEs in patients who entered 3-yr long-term safety follow-up (safety population)
Radium-223
n = 405
Placebo
n = 167
Radium-223 (main study and
placebo crossover)
n = 420
AEs, n (%) All Gr Gr 3/4 Gr 5 All Gr Gr 3/4 Gr 5 All Gr Gr 3/4 Gr 5
Hematologic
Anemia 11 (3) 5 (1) 0 5 (3) 1 (1) 0 11 (3) 5 (1) 0
Aplastic anemia 1 (<1) 1 (<1) 0 0 0 0 1 (<1) 1 (<1) 0
Leukopenia 2 (<1) 2 (<1) 0 0 0 0 2 (<1) 2 (<1) 0
Neutropenia 2 (<1) 2 (<1) 0 0 0 0 3 (1) 3 (1) 0
Thrombocytopenia 3 (1) 0 0 0 0 0 3 (1) 0 0
Pancytopenia 0 0 0 0 0 0 1 (<1) 1 (<1) 0
Nonhematologic
Cardiopulmonary failure 0 0 0 1 (1) 0 1 (1) 0 0 0
Constipation a 1 (<1) 0 1 (<1) 0 0 0 1 (<1) 0 1 (<1)
Diarrhea 1 (<1) 1 (<1) 0 0 0 0 1 (<1) 1 (<1) 0
Vomiting 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Nausea 0 0 0 1 (1) 0 0 0 0 0
Fatigue 1 (<1) 0 0 1 (1) 0 0 1 (<1) 0 0
General physical health deterioration 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Multiorgan failure a 1 (<1) 0 1 (<1) 0 0 0 1 (<1) 0 1 (<1)
Pneumonia 1 (<1) 0 1 (<1) 0 0 0 1 (<1) 0 1 (<1)
Weight decrease 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Anorexia 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Musculoskeletal pain 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Osteonecrosis 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Pathologic fracture 2 (<1) 1 (<1) 0 0 0 0 2 (<1) 1 (<1) 0
Dizziness 1 (<1) 0 0 0 0 0 1 (<1) 0 0
Hematochezia 0 0 0 0 0 0 1 (<1) 0 0
Neutropenic sepsis 0 0 0 0 0 0 1 (<1) 1 (<1) 0
Femoral neck fracture 0 0 0 0 0 0 1 (<1) 1 (<1) 0
AEs = adverse events; Gr = grade.
a Patient died of multiorgan failure due to necrosis of the large intestine; onset of grade 5 constipation and death occurred on the same day.
E U RO P E AN URO L OGY 7 3 ( 2 0 1 8 ) 4 2 7 – 4 3 5 433six radium-223 injections. One patient died of pneumonia
8.4 mo from the last injection, and one died of multiorgan
failure 18.1 mo from the last injection.
4. Discussion
Consistent with previous analyses [9,12–14], this updated
final long-term safety follow-up analysis from ALSYMPCA
trial in CRPC patients with symptomatic bone metastases
showed that radium-223 continued to be well tolerated,
with a low incidence of myelosuppression, long-term
preservation of hematopoietic function, and no new safety
signals.
Radium-223 compares well in safety with the hormonal
therapies abiraterone and enzalutamide [15–19], but is
unlike the cytotoxic chemotherapies, in which myelosup-
pression is the most frequent AE [20,21]. In the phase
3 TROPIC study, treatment with cabazitaxel was associated
with significant myelosuppression (all grades neutropenia
[94%], leukopenia [96%], anemia [97%], and thrombocyto-
penia [47%]) with relatively high rates of febrile neutrope-
nia (8%) [4]. Furthermore, neutropenia frequently occurs in
docetaxel-treated patients [20]. Radium-223 is also distinct
from the beta-emitting radiopharmaceuticals, which are
associated with significant hematologic AEs (mainly leuko-
penia and thrombocytopenia) [22,23].
In this 3-yr long-term safety analysis, secondary
malignancies occurred in four radium-223 patients andthree placebo patients. The percentages of radium-223 and
placebo patients who received anticancer medications and
radiotherapies during follow-up were generally similar.
A study limitation is that assessment of long-term
radium-223 safety may be difficult given that many
participants were treated with other anticancer therapies
in combination with radium-223 during the follow-up
period. Secondary malignancies induced by cancer thera-
pies are of clinical interest, as they are a cause of morbidity
and mortality in long-term cancer patients. Although
secondary malignancies are uncommon, they can be a
serious consequence of radiotherapy for cancer treatment
[24]. None of the secondary malignancies were considered
related to radium-223, and no new primary bone cancer
was reported; however, another study limitation was that
the follow-up was limited to 3 yr, which is a relatively short
time to assess the number of treatment-induced cancers,
including hematologic malignancies. Additional studies
with longer follow-up times are necessary to more
accurately assess the long-term safety of radium-223.
Another study limitation was that AEs were reported
during follow-up only if considered by the investigator to be
treatment related and may therefore be under-reported.
Enrollment is currently ongoing in an international,
prospective, observational, single-arm study (Radium-223
Alpha Emitter Agent in Safety Study in mCRPC Population
for Long-Term Evaluation) aiming to assess the incidence of
second primary malignancies in CRPC patients with bone
E U RO P E AN URO LOG Y 7 3 ( 2 0 1 8 ) 4 2 7 – 4 3 5434metastaseswho are receiving radium-223 in routine clinical
practice. Patients will be followed until 7 yr after the last
radium-223 dose (NCT02141438).
Of the patients who entered long-term safety follow-up,
a higher percentage of radium-223 patients compared with
placebo patients were alive at the end of the 3-yr period
(14% vs 7%). These results, together with the unique
mechanism of action and favorable safety profile during
treatment and follow-up periods, make radium-223 an
important treatment option, with potential for sequencing
and combination with other agents for CRPC patients.
The current safety profile of radium-223 is based on a
treatment course of six injections (50 kBq/kg [55 kBq/kg
following the NIST update]) [11] given at 4-wk intervals.
Studies are ongoing with higher-dose or extended-dose
radium-223 regimens (NCT02023697) and combinationwith
other agents (NCT02034552 [radium-223 + abiraterone or
enzalutamide], NCT02043678 [radium-223 + abiraterone +
prednisone/prednisolone], NCT01106353 [radium-223 +
docetaxel]). Results from a phase 1/2 international, multi-
center, prospective study in a highly selected population of
patients with CRPC and bonemetastases whowere retreated
with six additional radium-223 doses (NCT01934790)
showed that retreatment with radium-223 was well
tolerated, with minimal hematologic toxicity [25]. Results
from these studies will further contribute to our under-
standing of the overall safety and efficacy of radium-223.
5. Conclusions
This updated final long-term safety follow-up ALSYMPCA
analysis shows that radium-223 is well tolerated in CRPC
patients with symptomatic bone metastases, with minimal
nonhematologic AEs, a low incidence of myelosuppression
with long-term preservation of hematopoietic function, and
no new safety signals.
5.1. Future perspectives
The safety of radium-223 combined with the unique
mechanism of action and prolongation of overall survival
suggests the possibility of combining it with other agents.
Additionally, earlier radium-223 use in patients with a low
bone disease burden has the potential advantage of
allowing patients to receive the recommended dosing
regimen of six injections and to sequence this agent with
subsequent therapies. Clinicians should consider using the
most efficacious and safest agents early in treatment,
thereby affording the possibility of allowing patients to
better tolerate subsequent therapies and achievemaximum
survival benefit. These updated ALSYMPCA safety data
provide support for using radium-223 treatment earlier in
the disease course, thus ensuring that patients achieve the
full six injections of radium-223, the regimen associated
with longer overall survival.
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